

# Chimerigen

## **C M** Mouse Fusion Proteins

[Home Page](#)[Fusion Protein](#)[Related Products](#)[Customized Services](#)

### Mouse CD152(CTLA4) /Fc Fusion Protein

**CATALOG#:** MF-120A4**QUANTITY:** 10 mg      **CONCENTRATION:** 1.0 mg/ml

**MOLECULAR STRUCTURE:** A soluble 110 kd dimeric fusion protein consisting of the extracellular (180aa) domain of mouse CD152(CTLA4) fused to mouse IgG2a Fc.

**TRANSFECTANT CELL LINE:** NS.1**INFORMATION:** Mouse CD152(CTLA4) /Fc Fusion Protein

**INFORMATION:** Immune response mediated by T cells can be characterized to functionally proceed as follows: antigen recognition by the T cell receptor, activation through costimulation, effector activities to eliminate antigen and finally down regulation. Mouse CD152 is a cell surface glycoprotein expressed at low levels on activated T cells (1). CD152 is a high affinity receptor for the costimulatory molecules CD80 (B7-1) and CD86 (B7-2) while CD28 binds to CD80 and CD86 with lower Affinity (2, 3). CD28 and CD152 play important roles in regulating the magnitude and nature of T cell mediated immune response. CTLA4/Fc, a soluble chimeric fusion protein, blocks the B7/CD28 signaling pathway by binding to CD80 and CD86 (1). CD152/Fc will block the binding of anti-CD80 (B7-1) and anti-CD86 (B7-2) monoclonal antibodies as well as block the interaction of CD80 and or CD86 with cell surface CD28 and or CD152 (4). Using CTLA4/Ig, many investigators have shown that interruption of the B7/CD28 pathway can lead to suppression of allo- and xenimmune responses, and, in some cases, induction of Ag-specific tolerance (5-7). However, by blocking B7 generated signals, CTLA4 Fc may prevent the negative regulatory CTLA4 signal (8-10).

**STORAGE CONDITIONS:** Store stock solution at -20<sup>0</sup>C. Store working solution at 4<sup>0</sup>C. Freeze/Thawing is not recommended.

**PRODUCT STABILITY:** Product should retain for at least one year after shipping date when stored at -20<sup>0</sup>C and the working solution should retain for at least one month at 4<sup>0</sup>C.

**BUFFER:** 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150 mM NaCl.

**PRODUCTION:** Mouse CTLA4 Ig fusion protein was purified from

serum free tissue culture supernatant of NS.1 transfectants. Purity was >99% by SDS-PAGE.

#### REFERENCES:

1. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med* 174:561.
2. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. *Annu Rev Immunol* 14:233.
3. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [published erratum appears in *Immunity* 1995 Feb;2(2):following 203]. *Immunity* 1:793.
4. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Linsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. *J Exp Med* 177:165.
5. Steurer, W., P. W. Nickerson, A. W. Steele, J. Steiger, X. X. Zheng, and T. B. Strom. 1995. Ex vivo coating of islet cell allografts with murine CTLA4 Fc promotes grafts tolerance. *J. Immunol.* 155:1165.
6. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. *Science* 257:789.
7. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, and T. C. Pearson. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. *Nature* 381:434.
8. Perez, V. L., L. V. Parijs, A. Biuckans, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vitro requires CTLA-4 engagement. *Immunity* 6:411.
9. Zheng, X. X., T. G. Markes, W. W. Hancock, Y. Li, D. L. Greiner, X. C. Li, J. P. Mordes, M. H. Sayegh, A. A. Rossini, and T. B. Strom. 1999. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. *J Immunol* 162:4983.
10. Judge, T. A., Z. Wu, X. G. Zheng, A. H. Sharpe, M. H. Sayegh, and L. A. Turka. 1999. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. *J Immunol* 162:1947.

\*This Product is intended for Laboratory Research use only.

---

**Fusion Proteins      Related Products      Customized Services**



**Join the Qantas eTravel Club...**

Creditreport.com: - Purchase your 3-in-1 credit report online for only \$28.95 and view it instantly!